Search

Displaying results 2701 - 2710 of 4207 in total
  1. Drug

    SB-249553

    go.drugbank.com/drugs/DB05285
    Experimental

    It is also under by GlaxoSmithKline to treat melanoma and lung cancer.

  2. Drug

    MaxAdFVIII

    go.drugbank.com/drugs/DB17713
    Experimental

    First developed by GenStar, it is being investigated for the treatment of hemophilia.

  3. Drug

    Befunolol

    go.drugbank.com/drugs/DB09013
    Experimental

    Befunolol is a beta blocker introduced in 1983 by Kakenyaku Kakko. It is currently in experimental status, and is being tested for the management of open angle glaucoma.

  4. Drug

    Sitagliptin

    go.drugbank.com/drugs/DB01261
    ApprovedInvestigational

    Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication ...

  5. Drug

    Moxonidine

    go.drugbank.com/drugs/DB09242
    ApprovedInvestigationalWithdrawn

    Moxonidine is a new-generation centrally acting antihypertensive drug approved for the treatment of mild to moderate essential hypertension. It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, AC...

  6. Drug

    AGA2115

    go.drugbank.com/drugs/DB17840
    Investigational

    Developed by Angitia Biopharmaceuticals, AGA2115 is being investigated for the treatment of osteogenesis imperfect.[L46646]

  7. Drug

    WP-1301

    go.drugbank.com/drugs/DB17702
    Experimental

    It binds to an MHC class II molecule and is recognized by a Factor VIII-specific T cell.[L46138]

  8. Drug

    Agatolimod

    go.drugbank.com/drugs/DB15018
    Investigational

    Agatolimod is under investigation in clinical trial NCT00471471 (Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery).

  9. Drug

    XT-150

    go.drugbank.com/drugs/DB21756
    Investigational

    [L52125] It is being developed by Xalud Therapeutics.

  10. Drug

    Pranlukast

    go.drugbank.com/drugs/DB01411
    Investigational

    It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.